Upstate Carolina Community Clinical Oncology Program

描述：(应聘者？S描述)积累了17年的工作经验 北卡罗来纳州社区临床肿瘤学项目(UC-CCOP) 寻求机会继续满足我们的社会？S需要创新 以及前景看好的治疗方式和癌症控制的相关研究 研究到2006年。该项目于1998年重新命名，之前 被称为斯帕坦堡CCOP。CCOP提供了访问国家合作社的途径 对9个县的80多万人进行的临床试验：6个在南方 卡罗莱纳州和北卡罗来纳州分别为3和3。南卡罗来纳州的人口密度和排名均为第21位 在医疗服务不足的百分比中排名第14。登记处的报告结束了 每年新增癌症患者2000人，自1995年以来几乎翻了一番。反对这一点 农村背景，一个五家医院联合体被开发用于开展 社区临床试验。服务区有17.4%的少数民族基础。 在少数人应计中表现出独特的能力(在治疗中超过22% 和在癌症控制方面排名靠前)，以及通过统计服务不足的条目：99个条目 在过去的5年里。CCOP汇集了以下方面的力量和资源 合作进行研究的多学科调查人员 SWOG、NSABP、RTOG、GOG、MDACC和维克森林大学癌症中心。 81名调查人员包括19名肿瘤学家和62名其他 纪律。UC-CCOP已为临床试验贡献了3000多个条目 自1983年以来，CCOP计划开始实施。在未来的五年里， 总体目标是通过以下方式降低癌症发病率、发病率和死亡率 加快转移新开发的癌症预防，及早 检测、治疗、病人管理、康复和持续护理 技术到广泛的社区应用，包括特别强调 患者管理试验，重点是探索使用 补充医学，并继续关注生活质量研究。 经过精心设计，该计划将把我们的资源集中在癌症控制上 研究的同时继续建立我们的治疗计划。这些相辅相成 治疗和癌症控制的目标都是现成的匹配 患者群体，符合CCOP的兴趣和能力。A农村 外展方案已经启动，并将继续增长。最直接的 CCOP的目标是继续增加我们的应计利润；保持广泛的 社区参与，包括少数群体和服务不足 NCI批准的治疗和癌症控制研究的人群； 维持并继续扩大我们非常大的癌症控制计划， 包括使用一系列资源来确定潜在的候选人 癌症控制研究项目。保持对乳腺癌的随访 预防试验(BCPT)，前列腺癌预防试验(PCPT)， 增加对STAR试验和其他项目的应计费用，并启动即将到来的SELECT 试验是主要目标。总而言之，CCOP的跟踪记录表明 管理复杂的临床研究和癌症控制活动的能力 同时产生最高质量的数据。CCOP拥有设施和 训练有素的专业人员为全方位的学习提供支持。这个 CCOP人员配置模式、方案管理程序、患者/参与者 管理方法、质量控制机制、内部评审委员会的结构和联络 都已到位并发挥作用，以支持当前和未来的治疗和 癌症控制活动。在新拨款的第一年(2001-2002)，我们 1)会为国家肿瘤研究所贡献近600个学分吗？S 社区临床肿瘤学计划：超过118个治疗积分和超过475个治疗积分 癌症控制学分和2)将服务于卡罗莱纳州作为全国 公认的卓越研究项目。

DESCRIPTION: (Applicant?s Description) Building on 17 years of experience as a CCOP, the Upstate Carolina Community Clinical Oncology Program (UC-CCOP) seeks the opportunity to continue to meet our community?s need for innovative and relevant studies of promising therapeutic modalities and cancer control research through the Year 2006. The program was re-named in 1998, previously known as Spartanburg CCOP. The CCOP provides access to national cooperative clinical trials to well over 800,000 people in 9 counties: 6 in South Carolina and 3 in North Carolina. SC is 21st in population density and ranks 14th in the percent who are medically underserved. The registries report over 2000 new cancer patients per year, nearly doubled since 1995. Against this rural background, a five hospital consortium was developed for the conduct of community clinical trials. The service area has a 17.4% minority base. Unique capacities are demonstrated in minority accrual (over 22% in treatment & ranking high in cancer control) and by accruing the underserved: 99 entries in the last 5 years. The CCOP brings together the strength and resources of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, RTOG, GOG, MDACC, and Cancer Center at Wake Forest University. The 81 investigators include 19 oncologists along with 62 colleagues in other disciplines. The UC-CCOP has contributed over 3000 entries to clinical trials since 1983, the start of the CCOP program. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application, including special emphasis on patient management trials, an emphasis on trials exploring the use of complementary medicine, and continued attention to Quality of Life research. By careful design, the program will focus our resources on cancer control research while continuing to build our treatment program. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within CCOP interests and capabilities. A rural outreach program has been initiated and will continue to grow. The immediate goals of the CCOP are to continue to increase our accrual; to maintain wide community participation, including minority groups and underserved populations, in both treatment and cancer control research approved by NCI; to sustain and continue to expand our very large cancer control program, including the use of a range of resources to identify potential candidates for cancer control research projects. To maintain Follow-Up to the Breast Cancer Prevention Trial (BCPT), the Prostate Cancer Prevention Trial (PCPT), to increase accrual to STAR trial and others, and to initiate the upcoming SELECT Trial are primary objectives. In summary, the CCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The CCOP has the facilities and well-trained professional personnel to support the full array of studies. The CCOP staffing pattern, protocol management procedures, patient/participant management approaches, quality control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. In the first year of new funding (2001-2002), we will 1) contribute nearly 600 credits to the National Cancer Institute?s Community Clinical Oncology Program: over 118 treatment credits and over 475 cancer control credits and 2) will serve the Carolinas as a nationally recognized research program of excellence.